<DOC>
	<DOCNO>NCT01414231</DOCNO>
	<brief_summary>This protocol part German AML Intergroup Trial , OSHO study arm compare common German standard arm randomization 9:1 ratio . The hypothesis involve primarily dose application AraC induction . It expect CR rate consequence also LFS high protocol use high AraC compare low dos LFS might superior study specific arm compare golden standard publish several year ago . In standard arm , AraC 100mg/m2/day give continuous infusion 7 day . Daunorubicin give 60 mg/m2/day two hour infusion day 3 , 4 und 5 . On day 22 second induction course apply . After reach CR , three cycle AraC 3 g/m2 three hour bid infused day 1 , 3 und 5 . In contrast OSHO arm consist induction therapy IDA 12 mg/m*2 20-30-min-iv day 1 - 3 AraC 2 x 1 g/m*2 bid 3-h-iv day 1+3+5+7 . A previous phase II study OSHO show high CR patient relapse AML use MitoFlag . In study ask question MitoFlag superior IdaAraC newly diagnose AML patient without CR first induction chemotherapy . Therefore patient randomize receive either MitoFlag IdaAraC difference CR rate evaluate . It still unclear two consolidation therapy need allogeneic autologous stem cell transplantation . This question address second part OSHO study , patient randomize receive either one two consolidation therapy . In study patient AML age 18-60 year except M3 enter</brief_summary>
	<brief_title>Comparison OSHO Protocol Standard Arm Protocol German AML Intergroup Patients With AML &lt; 60a</brief_title>
	<detailed_description />
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<criteria>Adult patient &lt; = 60 year acute myelogenous leukemia ( AML ) AML ( 8 ; 21 ) ( q22 ; q22 ) , AML1 ( CBFa ) /ETO , AML ( inv ( 16 ) ( p13q22 ) ) und variant ( CBFb/MYH11 ) , AML 11q23 , MLLanomalies , AML normal karyotyp myelodysplastic syndrome ( MDS ) RAEBT 2030 % blast . de novo AML secundary AML MDS secundary AML chemotherapy alkylantien sekund√§re AML chemotherapy Epipodophyllotoxin inform consent AML M3 patient include another clinical trial contraindication high dose cytotoxic therapy renal insufficiency liver insufficiency cardiac insufficiency NYHA III + IV , acute myocardial infarction uncontroled infection like pneumonia hypoxemia septic schock pregnancy KarnofskiIndex 10 less second maligancy severe , decompensated metabolism disorder</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>April 2008</verification_date>
	<keyword>AML</keyword>
	<keyword>acute myeloid leukaemia</keyword>
	<keyword>low v intermediate dose AraC</keyword>
	<keyword>CR rate</keyword>
	<keyword>patient &lt; 60 year</keyword>
</DOC>